Company: PTPI
Filing Date: 2025-02-13
Form Type: S-1/A
Source: 0001410578-25-000122
Chunk: 82

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-13
Form: S-1/A
Chunk 82
---
 officers of the Company, subject to the closing of this offering, and (iii) any exercise of the Series Warrants or conversion of the Series B Preferred Stock underlying the Series Warrants. The discussion and table above are based on 10,014,872 shares of our common stock outstanding as of September 30, 2024, and excludes the following:

| ● | 8,188,742 shares of common stock issuable upon exercise of the Company’s outstanding warrants at an average weighted exercise of $14.49 per share; |

| ● | 509,133 shares of common stock underlying outstanding options of the Company, with a weighted average exercise price of $4.75 per share; |

| ● | 560,171 shares of common stock issuable upon conversion of the 1,039 shares of the Company’s Series A Preferred Stock outstanding, at a conversion price equal to $2.25 per share; and |

| ● | 2,158,658 shares of common stock reserved for issuance under the Plan. |

45

Dilution If you invest in our common stock and/or Pre-Funded Warrants in this offering, your ownership interest will be diluted immediately to the extent of the difference between the assumed public offering price per share of our common stock underlying the Units and the pro forma as adjusted net tangible book value per share of our common stock after this offering. Our net tangible book value as of September 30, 2024, was $(6,834,620), or approximately $(0.68) per share of our common stock. Net tangible book value per share is equal to our total tangible assets less our mezzanine equity and total liabilities, divided by the number of shares of our outstanding common stock. Our pro forma net tangible book value (deficit) as of September 30, 2024, after Vivus Adjustments was $(8,972,238) or approximately $(0.90) per share. After giving further effect to (i) the sale of Units in this offering at the assumed public offering price of $0.269 per share (the last reported sale price of our common stock on The Nasdaq Capital Market on February 6, 2025), and after deducting the placement agent fees and estimated offering expenses payable by us, and excluding the proceeds, if any, from the cash exercise of the Series Warrants issued in this offering and assuming no Pre-Funded Warrants are issued in this offering, and (ii) the Pro Forma Adjustments